/

CDNA

CareDx, Inc.Pre-market

63.12−0.55 −0.86%USD

NasdaqGM · as of Oct 12, 16:00 ET · 15m delayPre-market 63.80 +1.08%

Open

63.28

Prev close

63.67

Day range

61.3764.47

52-week range

14.0372.51

Volume

898.94K0.69×

Mkt cap

3.27B

P/E ttm

30.35

Fwd P/E

48.93

EPS ttm

2.08

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−12.95%

Price Chart

Yahoo Finance · delayed

CDNAOct 12, 2026O 63.28H 64.47L 61.34C 63.12−0.55 (−0.86%)Vol 900.00K

SMA 5053.44
SMA 20030.10

1Y change +338.64% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CDNA CareDx, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −9.63%
1 month: +25.59%
3 months: +119.47%
6 months: +275.04%
Year to date: +235.03%
1 year: +338.64%

Valuation & ownership

Market cap: 3.27B
Enterprise value: 2.91B
P/E (ttm): 30.35
Forward P/E: 48.93
PEG ratio: —
Price / book: 7.64
Price / sales (ttm): 7.13
EV / EBITDA: 234.14
EPS (ttm): 2.08
EPS (forward): 1.29
Beta (5y monthly): 2.38
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 51.73M
Float: 49.46M
Short % of float: 12.97%
Short ratio (days): 5.19
Held by insiders: 3.10%
Held by institutions: 104.06%
Avg volume (3m): 1.31M
50-day average: 53.44
200-day average: 30.10
52-week change: +338.64%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 60.1
vs 50-day SMA: +18.12%
vs 200-day SMA: +109.71%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.29%
Realised vol (20d, ann.): 63.2%
From 52-week high: −12.95%
From 52-week low: +349.89%

ANR

Analyst Consensus

6 analysts

Consensus

Buy

1.57 on a 1 (strong buy) – 5 (sell) scale

Mean target

58.83

−6.79% implied

Low 46.00Median 61.00High 74.00

Recommendation trend

Now5 / 2 / 0
1m ago4 / 3 / 0

DES

About CareDx, Inc.

Yahoo Finance profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Sector: Healthcare
Industry: Diagnostics & Research
Employees: 761
Headquarters

SEAS

Seasonality · CDNA

2014–2026 · monthly returns

Strongest month Aug +16.43%Weakest month Mar −8.30%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	9.1	-8.7	-7.5	19.9	9.7	24.9	53.4	14.6	29.7	-2.9			+235.0%
2025	8.8	-4.9	-19.9	-4.9	0.7	15.0	-37.1	11.2	6.4	3.2	19.1	5.4	−12.0%
2024	-28.7	24.3	-0.5	-26.7	67.7	19.4	28.7	53.7	1.6	-29.1	10.9	-12.8	+78.4%
2023	30.9	12.6	-45.7	-11.5	-1.4	6.5	28.4	-14.7	-24.8	-22.7	79.5	23.6	+5.2%
2022	-8.1	-8.2	-3.6	-17.7	-17.4	-14.6	10.8	-17.7	-13.1	17.0	-35.0	-11.9	−74.9%
2021	5.5	3.5	-13.9	16.1	1.7	13.8	-8.2	-12.8	-13.5	-19.5	-15.4	5.4	−37.2%
2020	12.0	-3.5	-6.3	16.3	26.6	10.3	-5.9	2.4	11.1	29.3	16.6	26.7	+235.9%
2019	11.5	11.0	1.3	-13.7	16.2	13.8	-8.9	-30.4	-0.9	15.9	-21.7	5.1	−14.2%
2018	-18.3	-3.0	36.9	22.8	35.2	-7.6	10.0	80.6	18.7	-9.5	12.1	-14.1	+242.5%
2017	-11.1	-12.5	-33.3	-37.9	18.4	7.8	19.8	115.0	29.4	58.1	24.1	1.1	+171.9%
2016	-23.4	-1.6	2.9	-10.5	0.0	-2.9	7.0	1.1	-23.8	2.8	-1.4	-25.0	−57.8%
2015	-2.6	-13.5	-9.2	-9.8	-3.6	34.9	0.6	6.0	-39.8	7.0	46.0	-1.7	−11.7%
2014								2.7	-29.8	-16.0	19.8	2.9	−25.3%

INSD

Insider Activity · CDNA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

311.8K shares

Sells, 6 months

350.3K shares

Net shares

−38.5K

Net change in insider shares

−2.30%

Date	Insider	Transaction	Shares	Value
Oct 1, 2026	Goldberg Michael DDirector	Stock Award(Grant) at price 0.00 per share.	588	—
Aug 4, 2026	Bickerstaff George W IiiDirector	Sale at price 46.28 per share.	20K	$925.70K
Aug 4, 2026	Novack Jeffrey AdamGeneral Counsel	Sale at price 46.15 - 46.75 per share.	2.7K	$124.35K
Aug 3, 2026	Cournoyer Christine MDirector	Sale at price 46.94 per share.	16K	$750.97K
Aug 3, 2026	Goldberg Michael DDirector	Sale at price 47.06 per share.	44.7K	$2.10M
Jul 15, 2026	Hanna John Walter JrChief Executive Officer	Sale at price 36.11 - 39.01 per share.	118K	$4.46M
Jul 15, 2026	Hanna John Walter JrChief Executive Officer	Conversion of Exercise of derivative security at price 8.20 per share.	118K	$967.60K
Jul 15, 2026	Valantine Hannah A.Director	Sale at price 36.14 - 36.55 per share.	28.8K	$1.04M
Jul 15, 2026	Valantine Hannah A.Director	Conversion of Exercise of derivative security at price 7.96 - 20.56 per share.	28.8K	$424.89K
Jul 1, 2026	Goldberg Michael DDirector	Stock Award(Grant) at price 0.00 per share.	1.7K	—
Jun 28, 2026	Hanna John Walter JrChief Executive Officer	Sale at price 29.00 - 29.24 per share.	40K	$1.17M
Jun 28, 2026	Hanna John Walter JrChief Executive Officer	Conversion of Exercise of derivative security at price 8.20 per share.	70K	$574.00K
Jun 14, 2026	Hanna John Walter JrChief Executive Officer	Sale at price 24.03 per share.	17.7K	$424.88K
Jun 14, 2026	Valantine Hannah A.Director	Sale at price 23.11 per share.	12.1K	$279.73K
Jun 11, 2026	Gunasekaran SureshDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
Jun 11, 2026	Riggsbee Richard BryanDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
Jun 11, 2026	Cournoyer Christine MDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
Jun 11, 2026	Cohen Frederick E. M.D. Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	9.8K	—
Jun 11, 2026	Goldberg Michael DDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
Jun 11, 2026	Bickerstaff George W IiiDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—

13F

Investors Holding CDNA

latest 13F filings of 29 followed managers

Investors holding CDNA
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$55.7M	0.36%	1.95M	−12%	Q2 2026
Renaissance Technologies	$35.4M	0.05%	1.24M	+4.9%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CDNA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CDNA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About CareDx, Inc.

Seasonality · CDNA

Insider Activity · CDNA

Congress Trades · CDNA

Investors Holding CDNA

Investors Holding CDNA

Congress Trades · CDNA

Insider Activity · CDNA

Seasonality · CDNA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About CareDx, Inc.

Financial Snapshot

Earnings & Dividends

News